Welcome to our dedicated page for Dice Therapeutics news (Ticker: DICE), a resource for investors and traders seeking the latest updates and insights on Dice Therapeutics stock.
DICE Therapeutics, Inc. (NASDAQ: DICE) is a clinical-stage biopharmaceutical company pioneering oral therapies for chronic immunological conditions through its proprietary DELSCAPE technology. Following its pending acquisition by Eli Lilly and Company, DICE remains focused on advancing innovative treatments that combine the efficacy of biologics with the convenience of oral administration.
This resource provides investors and healthcare professionals with timely updates on DICE's clinical developments, regulatory milestones, and strategic initiatives. Users will find verified information on key areas including progress of IL-17 inhibitors for autoimmune disorders, advancements in inflammatory bowel disease therapies, and integration updates related to the Eli Lilly partnership.
All content is curated to support informed decision-making while maintaining strict compliance with financial disclosure standards. Bookmark this page for centralized access to DICE's official announcements, ensuring you stay current with developments impacting both patient care and investment considerations in the biopharmaceutical sector.
DICE Therapeutics, Inc. (Nasdaq: DICE) reported its first quarter 2022 results, showing a cash position of $303.2 million, expected to fund operations through mid-2024. The company continues its Phase 1 clinical trial of oral IL-17 antagonist, DC-806, with topline proof-of-concept data anticipated in mid-2022. R&D expenses increased to $13.4 million from $6.6 million year-over-year, driven by advancements in the IL-17 franchise. The net loss for Q1 2022 was $18.6 million, a significant rise from $8.1 million in Q1 2021.
DICE Therapeutics, a biopharmaceutical company focusing on oral therapeutics for chronic diseases, will present at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 1:20 p.m. PT. The event will be accessible via a live and archived webcast on the Company’s website.
DICE is leveraging its DELSCAPE platform to develop oral candidates targeting IL-17, α4ß7 integrin, and αVß1/αVß6 integrin for conditions in immunology, inflammatory bowel disease, and idiopathic pulmonary fibrosis, aiming for comparable efficacy to systemic biologics.
ShouTi Inc., a clinical-stage biopharmaceutical company, has appointed Sharon Tetlow to its board of directors, where she will also chair the audit committee. With over 30 years of experience in life sciences finance, Tetlow has previously held senior roles including CFO at various biopharmaceutical firms. She currently serves on the boards of Dice Therapeutics (DICE), Valneva SE (VALN), and Catalyst Biosciences (CBIO). Her expertise is expected to strengthen ShouTi's growth strategy as the company focuses on developing innovative oral therapeutics for chronic diseases.
DICE Therapeutics, Inc. has appointed Mary Riley, J.D., as general counsel and added Lisa Bowers and Mittie Doyle, M.D., FACR, to its board of directors, enhancing its leadership team. Mary Riley brings 15 years of legal experience from Genentech, focusing on litigation and business law. Lisa Bowers, with a strong background in commercial leadership, and Mittie Doyle, a seasoned clinical development expert, will contribute significantly to DICE's biopharmaceutical initiatives. Concurrently, Stephen Zachary, Ph.D., has stepped down from the board. These changes aim to support DICE's growth in developing novel oral therapeutics targeting chronic diseases.
DICE Therapeutics, Inc. (Nasdaq: DICE) reported notable progress in its clinical trials and solid financial standing as of December 31, 2021. The company is on track to release topline data from its Phase 1 trial of oral IL-17 antagonist DC-806 in mid-2022, while DC-853 has been nominated as a new development candidate. DICE's cash position of $319.3 million is expected to sustain operations through mid-2024, supporting upcoming clinical milestones. However, R&D expenses increased significantly, resulting in a net loss of $49 million for 2021.
DICE Therapeutics, based in South San Francisco, has announced management's upcoming presentation at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 p.m. ET.
The company focuses on developing oral therapeutics for chronic diseases, particularly in immunology, using its proprietary DELSCAPE platform. DICE's lead candidate, S011806, targets IL-17, a molecule involved in inflammation. Interested parties can access a live and archived webcast of the presentation on their website for 90 days post-event.
DICE Therapeutics, a biopharmaceutical company focused on innovative oral therapeutics for chronic diseases, will participate in two investor conferences this November. Management will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22 at 10:00 a.m. ET, followed by a session at the 4th Annual Evercore ISI HealthCONx Conference on November 30 at 3:55 p.m. ET. Webcasts of both events will be available on the company's website. DICE is advancing oral candidates targeting significant immunology pathways, including IL-17, for enhanced therapeutic outcomes.
DICE Therapeutics (Nasdaq: DICE) successfully completed a $234.6 million upsized initial public offering, with 13,800,000 shares sold at $17.00 each. The company also dosed its first healthy volunteers in a Phase 1 clinical trial for S011806, an oral IL-17 antagonist aimed at treating psoriasis. DICE's cash and cash equivalents stand at $335.7 million, expected to fund operations through the end of 2023. R&D expenses rose to $11.7 million for Q3 2021, compared to $4.5 million in Q3 2020, reflecting increased personnel and preclinical advancement.
DICE Therapeutics (Nasdaq: DICE) announced the dosing of the first healthy volunteer in its Phase 1 clinical trial for S011806, an oral antagonist targeting IL-17, on October 25, 2021. This first-in-human trial aims to evaluate the safety, pharmacokinetics, and early efficacy of S011806 in psoriasis patients. With over 8 million Americans suffering from psoriasis, this trial represents a significant milestone in developing oral therapies for IL-17 mediated diseases. Successful outcomes could lead to S011806 becoming a viable alternative to injectable biologics.
DICE Therapeutics, Inc. announced the pricing of its upsized IPO, offering 12,000,000 shares at $17.00 each, aiming for gross proceeds of $204 million. All shares are offered by DICE, and trading on Nasdaq under the ticker symbol 'DICE' starts on September 15, 2021. The offering is set to close on September 17, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 1,800,000 more shares. The company focuses on developing novel oral therapeutics for chronic diseases in immunology.
FAQ
What is the market cap of Dice Therapeutics (DICE)?
